Vascular endothelial growth factor administration does not improve microvascular disease in the salt-dependent phase of post-angiotensin II hypertension

American Journal of Physiology - Renal Physiology

Volumn 291, Issue 6, 2006, Pages

  Long, David A ^a,b   Mu, Wei ^a   Price, Karen L ^a   Roncal, Carlos ^a   Schreiner, George F ^c   Woolf, Adrian S ^b   Johnson, Richard J ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Toyota Technical Center USA Inc   (United States)

Author keywords

Blood vessels; Vascular growth factors

Indexed keywords

ANGIOTENSIN II; DRUG VEHICLE; NITRITE; VASCULOTROPIN 121;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; HYPERTENSION; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; MALE; MICROANGIOPATHY; NONHUMAN; PRIORITY JOURNAL; RAT; SODIUM RESTRICTION; UREA NITROGEN BLOOD LEVEL;

EID: 33845370437     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00096.2006     Document Type: Article

References (44)

1. Baylis C and Vallance P. Measurement of nitrite and nitrate levels in plasma and urine-what does this measure tell us about the activity of the endogenous nitric oxide system? Curr Opin Nephrol Hypertens 7: 59-62, 1998.
2. Chen J, Zhang ZG, Li Y, Wang L, Xu YX, Gautam SC, Lu M, Zhu Z, and Chopp M. Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ Res 92: 692-699, 2003.
3. Couper LL, Bryant SR, Eldrup-Jorgensen J, Bredenberg CE, and Lindner V. Vascular endothelial growth factor increases the mitogenic response to fibroblast growth factor-2 in vascular smooth muscle cells in vivo via expression of fms-like tyrosine kinase-1. Circ Res 81: 932-939, 1997.
4. Distler O, Distler JHW, Scheid A, Acker T, Hirth A, Rethage J, Michel BA, Gay RE, Muller-Ladner U, Matucci-Cerinic M, Plate KH, Gassmann M, and Gay S. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 95: 109-116, 2004.
5. Elger M, Sakai T, and Kriz W. The vascular pole of the renal glomerulus of rat. Adv Anat Embryol Cell Biol 139: 1-98, 1998.
6. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Milner JH, and Quaggin SE. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111: 707-716, 2003.
7. Feliers D, Duraisamy S, Barnes JL, Ghosh-Choudhury G, and Kasinath BS. Translational regulation of vascular endothelial growth factor expression in renal epithelial cells by angiotensin II. Am J Physiol Renal Physiol 288: F521-F529, 2005.
8. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 56: 794-814, 1999.
9. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, and Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51: 3090-3094, 2002.
10. Franco M, Tapia E, Santamaria J, Zafra I, Garcia-Torres R, Gordon KL, Pons H, Rodriguez-Iturbe B, Johnson RJ, and Herrera-Acosta J. Renal cortical vasoconstriction contributes to development of salt-sensitive hypertension after angiotensin II exposure. J Am Soc Nephrol 12: 2263-2271, 2001.
11. Furst DE and Clements PJ. Pathogenesis fusion (summary). In: Systemic Sclerosis, edited by Furst DE and Clements PJ. Baltimore, MD: Williams and Wilkins, 1996, p. 275-284.
12. Johnson RJ, Herrera-Acosta J, Schreiner GF, and Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 346: 913-923, 2002.
13. Kanellis J, Bakris GL, Kurokawa K, and Johnson RJ. Pathogenesis and clinical course of essential hypertension. In: Comprehensive Clinical Nephrology, edited by Johnson RJ and Feehally J. Philadelphia, PA: Mosby, 2003, p. 477-488.
14. Kang DH, Hughes J, Mazzali M, Schreiner GF, and Johnson RJ. Impaired angiogenesis in the remnant kidney model. II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 12: 1448-1457, 2001.
15. Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, Gordon KL, Mazzali M, Jefferson JA, Hughes J, Madsen KM, Schreiner GF, and Johnson RJ. Impaired angiogenesis in the remnant kidney model. I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 12: 1434-1447, 2001.
16. Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, Schreiner GF, and Johnson RJ. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 13: 806-816, 2002.
17. Kang DH, Kim YG, Andoh TF, Gordon KL, Suga S, Mazzali M, Jefferson JA, Hughes J, Bennett W, Schreiner GF, and Johnson RJ. Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor. Am J Physiol Renal Physiol 280: F727-F736, 2001.
18. Kawaguchi Y, Takagi K, Hara M, Fukasawa C, Sugiura T, Nishimagi E, Harigai M, and Kamatani N. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type I receptors. Arthritis Rheum 50: 216-226, 2004.
19. Kim YG, Suga SI, Kang DH, Jefferson JA, Mazzali M, Gordon KL, Matsui K, Breiteneder-Geleff S, Shankland SJ, Hughes J, Kerjaschki D, Schreiner GF, and Johnson RJ. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int 58: 2390-2399, 2000.
20. Lombardi D, Gordon KL, Polinsky P, Suga S, Schwartz SM, and Johnson RJ. Salt-sensitive hypertension develops after short-term exposure to angiotensin II. Hypertension 33: 1013-1019, 1999.
21. Long DA, Price KL, Herrera-Acosta J, and Johnson RJ. How does angiotensin II cause renal injury? Hypertension 43: 722-723, 2004.
22. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, and Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649-658, 2003.
23. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, and Hughes J. Osteopontin-a molecule for all seasons. QJM 95: 3-13, 2002.
24. Miyamoto K, Kitamoto Y, Tokunaga H, Takeya M, Ezaki T, Imamura T, and Tomita K. Protective effect of vascular endothelial growth factor/vascular permeability factor 165 and 121 on glomerular endothelial cell injury in the rat. Lab Invest 84: 1126-1136, 2004.
25. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, Kerarney M, Chen D, Chen D, Symes JF, Fishman MC, Huang PL, and Isner JM. Nitric oxide modulates angiogenesis in response to tissue ischemia. J Clin Invest 101: 2567-2578, 1998.
26. Nakagawa T, Sato W, Sautin YY, Glushakova O, Croker B, Atkinson MA, Tisher CC, and Johnson RJ. Uncoupling of vascular endothelial growth factor with nitric oxide as a mechanism for diabetic vasculopathy. J Am Soc Nephrol 17: 736-745, 2006.
27. Ohashi R, Shimizu A, Masuda Y, Kitamura H, Ishizaki M, Sugisaki Y, and Yamanaka N. Peritubular capillary regression during the progression of experimental obstructive nephropathy. J Am Soc Nephrol 13: 1795-1805, 2002.
28. Papapetropoulos A, Garcia-Carden G, Madri JA, and Sessa WC. Nitric oxide production contributes to the angiogenic properties of VEGF in human endothelial cells. J Clin Invest 100: 3131-3139, 1997.
29. Pillebout E, Burtin M, Yuan HT, Briand P, Woolf AS, Friedlander G, and Terzi F. Proliferation and remodeling of the peritubular microcirculation after nephron reduction: association with the progression of renal lesions. Am J Pathol 159: 547-560, 2001.
30. Pugh CW and Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9: 677-684, 2003.
31. Pupilli C, Lasagni L, Romagnani P, Bellini F, Mannelli M, Misciglia N, Mavilia C, Vellei U, Villari D, and Serio M. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. J Am Soc Nephrol 10: 245-255, 1999.
32. Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J, and Johnson RJ. Oxidative stress, renal inflammation of immune cells, and salt-sensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol 286: F606-F616, 2004.
33. Sanchez-Lozada LG, Tapia E, Avila-Casado C, Soto V, Franco M, Santamaria J, Nakagawa T, Rodriguez-Iturbe B, Johnson RJ, and Herrera-Acosta J. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 283: F1105-F1110, 2002.
34. Schrijvers BF, Flyvbjerg A, and De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65: 2003-2017, 2004.
35. Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, Kurokawa K, and Fujita T. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 42: 31-38, 2003.
36. Shen BQ, Lee DY, and Zioncheck TF. VEGF governs endothelial NO synthase expression via a KDR/Flk-1 receptor and a protein kinase C signalling pathway. J Biol Chem 274: 33057-33063, 1999.
37. Shimizu A, Masuda Y, Mori T, Kitamura H, Ishizaki M, Sugisaki Y, and Fukuda Y. Vascular endothelial growth factor 165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat antiglomerular basement membrane glomerulonephritis. J Am Soc Nephrol 15: 2655-2665, 2004.
38. Suga S, Kim YG, Joly A, Puchacz E, Kang DH, Jefferson JA, Abraham JA, Hughes J, Johnson RJ, and Schreiner GF. Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy. Kidney Int 60: 1297-1308, 2001.
39. Wang H and Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circ Res 83: 832-840, 1998.
40. Williams B, Baker AQ, Gallacher B, and Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 25: 913-917, 1995.
41. Yuan HT, Li XZ, Pitera JE, Long DA, and Woolf AS. Peritubular capillary loss after mouse acute nephrotoxicity correlates with downregulation of vascular endothelial growth factor-A and hypoxia-inducible factor-1 alpha. Am J Pathol 163: 2289-2301, 2003.
42. Yuan HT, Tipping PG, Li XZ, Long DA, and Woolf AS. Angiopoietin correlates with glomerular capillary loss in anti-glomerular basement membrane glomerulonephritis. Kidney Int 61: 2078-2089, 2002.
43. Zhao Q, Ishibashi M, Hiasa KI, Tan C, Takeshita A, and Egashira K. Essential role of vascular endothelial growth factor in angiotensin II induced vascular inflammation and remodelling. Hypertension 44: 264-270, 2004.
44. Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Grangert HJ, and Bicknell R. Nitric oxide synthase lies downstream from VEGF-induced but not bFGF-induced angiogenesis. J Clin Invest 99: 2625-2634, 1997.